Abstract
The TRP family of cation-permeable channels owes its name to a Drosophila TRP mutant with impaired vision due to transient rather than sustained receptor potential. Mammalian TRP channels can be grouped into 6 subfamilies, including TRPC, TRPM, TRPV, TRPA, TRPP and TRPML and a number of TRP family members have been identified in the vasculature. TRP channels play an important functional role in the vasculature as mediators of cation influx across the plasma membrane, thus contributing to a large number of processes such as vascular smooth muscle contraction and vascular pressure or the responses to oxidative stress, mechanical stimuli, heat and hypoxia-induced vascular remodelling. TRP channelopaties are involved in the pathogenesis of different disorders including hypertension and cardiomyopathy. A number of identified natural compounds and synthetic agents have been reported to modulate TRP function, and are the base for therapeutical strategies.
Keywords: TRP, smooth muscle cells, endothelial cells.
Current Vascular Pharmacology
Title:Pharmacology of TRP Channels in the Vasculature
Volume: 11 Issue: 4
Author(s): Isaac Jardin, Natalia Dionisio, Jose J. Lopez, Gines M. Salido and Juan A. Rosado
Affiliation:
Keywords: TRP, smooth muscle cells, endothelial cells.
Abstract: The TRP family of cation-permeable channels owes its name to a Drosophila TRP mutant with impaired vision due to transient rather than sustained receptor potential. Mammalian TRP channels can be grouped into 6 subfamilies, including TRPC, TRPM, TRPV, TRPA, TRPP and TRPML and a number of TRP family members have been identified in the vasculature. TRP channels play an important functional role in the vasculature as mediators of cation influx across the plasma membrane, thus contributing to a large number of processes such as vascular smooth muscle contraction and vascular pressure or the responses to oxidative stress, mechanical stimuli, heat and hypoxia-induced vascular remodelling. TRP channelopaties are involved in the pathogenesis of different disorders including hypertension and cardiomyopathy. A number of identified natural compounds and synthetic agents have been reported to modulate TRP function, and are the base for therapeutical strategies.
Export Options
About this article
Cite this article as:
Jardin Isaac, Dionisio Natalia, Lopez J. Jose, Salido M. Gines and Rosado A. Juan, Pharmacology of TRP Channels in the Vasculature, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040011
DOI https://dx.doi.org/10.2174/1570161111311040011 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
OPA1 in Cardiovascular Health and Disease
Current Drug Targets Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics
Current Proteomics Turning REST/NRSF Dysfunction in Huntingtons Disease into a Pharmaceutical Target
Current Pharmaceutical Design Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Induction of Myocardial Fibrosis and Hypertrophy by Natriuretic Peptides
Vascular Disease Prevention (Discontinued) Comparison of Granulomatosis with Polyangiitis Clinical Features in Patients Depending on Involvement or Absence of Kidney Involvement
Current Rheumatology Reviews Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Chaperone Therapy: New Molecular Therapy for Protein Misfolding Diseases with Brain Dysfunction
Current Bioinformatics TTR Fibril Formation Inhibitors: Is there a SAR?
Current Medicinal Chemistry Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Cardiovascular & Hematological Disorders-Drug Targets Dysregulation of Glycogen Synthase Kinase-3 in Skeletal Muscle and the Etiology of Insulin Resistance and Type 2 Diabetes
Current Diabetes Reviews Mesenchymal Stem Cell Therapy for Patients with Ischemic Heart Failure- Past, Present, and Future
Current Stem Cell Research & Therapy The Role of Trimetazidine After Acute Myocardial Infarction
Current Vascular Pharmacology B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Potential of Sulphur-containing Amino Acids in the Prevention of Catecholamine-induced Arrhythmias
Current Medicinal Chemistry